Tafas v. Dudas et al Doc. 83 Att. 4

Case 1:07-cv-00846-JCC-TRJ Document 83-5 Filed 11/26/2007 Page 1

Defendants' Exhibit 2

UNITED STATES DISTRICT COURT
EASTERN DISTRICT OF VIRGINIA

EASTERN DISTRICT OF VIRGINIA
Alexandria Division

TRIANTAFYLLOS TAFAS,

AFYLLOS TAFAS, Plaintiff,

-vs-

Case No. 1:07-cv-846

JON W. DUDAS, et al., Defendants.

HEARING ON MOTIONS

November 16, 2007

BEFORE: T. Rawles Jones, Jr., Magistrate Judge

APPEARANCES:

James E. Nealon, Joseph D. Wilson or Steven J. Moore, Counsel for the Plaintiff

Lauren A. Wetzler, Ralph A. Price, Jr. and R. Joseph Sher, Counsel for the Defendant

John Desmarais, F. Christopher Mizzo and Michael McGettigan, Counsel for SKB Corp.

log. Ms. Wetzler was kind enough to write back and say, can you send me authority about whether one is-- So, the parties are still discussing that. And that issue wasn't briefed.

Additionally, we have served FOIA requests to get information that supports the administrative record. Those are working its way through the Patent Office. The Patent Office is not asking to quash those by this motion. So, we wouldn't want any order from the Court to do that because the Patent Office even agrees that those are appropriate.

When we get the answers back from those FOIA requests depending upon what the answers are, that may lead to targeted discovery that we may need to do at that point.

So, my only request would be from GSK that Your Honor not issue any order that would be blanket prohibition, that we take the discovery requests as they come up and address today only whether these four deposition notices are appropriate because there may be as we go forward in the case, remember, we are at the very beginning of the case, as we get the answers to the FOIA requests and as we negotiate with the Patent Office whether they are going to give us a privilege log, there may be targeted discovery that would be relevant.

And I find it, you know, today discussing what might be appropriate as we move forward in the case much like it would be an advisory opinion. You know, the record is still developing, we are still moving forward, we still negotiating.